Effect of Atorvastatin on CYP2C9 Metabolic Activity as Measured by the Formation Rate of Losartan Metabolite in Hypercholesterolaemic Patients

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 2, 2011, Pages 73-77

  Yasar, Umit ^a   Sain Guven, Gulay ^a   Yardimci, Yildiz ^a   Kilicarslan, Alpaslan ^a   Babaoglu, Melih O ^a   Bozkurt, Atilla ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ATORVASTATIN; CYTOCHROME P450 2C9; LOSARTAN;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ARYL HYDROCARBON HYDROXYLASES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LOSARTAN; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES;

EID: 79960211218     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00687.x     Document Type: Article

References (42)

1. Martin JH, Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007;113:119-27.
2. Tiwari A, Bansal V, Chugh A, Mookhtiar K. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf 2006;5:651-66.
3. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010;33:171-87.
4. Davidson MH. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther 2001;6:219-29.
5. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81.
6. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105.
7. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-15.
8. Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc (Wash) 2000;40:637-44.
9. El-Sankary W, Gibson GG, Ayrton A, Plant N. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001;29:1499-504.
10. Kocarek TA, Dahn MS, Cai H, Strom SC, Mercer-Haines NA. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos 2002;30:1400-5.
11. Kobayashi K, Yamanaka Y, Iwazaki N, Nakajo I, Hosokawa M, Negishi M et al. Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 2005;33:924-9.
12. Fisslthaler B, Michaelis UR, Randriamboavonjy V, Busse R, Fleming I. Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim Biophys Acta 2003;1619:332-9.
13. Bertrand-Thiebault C, Masson C, Siest G, Batt AM, Visvikis-Siest S. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line. J Cardiovasc Pharmacol 2007;49:306-15.
14. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006;26:1601-7.
15. Kline SS, Harrell CC. Potential warfarin-fluvastatin interaction. Ann Pharmacother 1997;31:790.
16. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother 1996;30:1399-402.
17. Iliadis EA, Konwinski MF. Lovastatin during warfarin therapy resulting in bleeding. Pa Med 1995;98:31.
18. Westergren T, Johansson P, Molden E. Probable warfarin-simvastatin interaction. Ann Pharmacother 2007;41:1292-5.
19. Sconce EA, Khan TI, Daly AK, Wynne HA, Kamali F. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost 2006;4:1422-4.
20. Stern R, Abel R, Gibson GL, Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol 1997;37:1062-4.
21. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89-295.
22. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 2004;76:113-8.
23. Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004;60:337-42.
24. Boruban MC, Yasar U, Babaoglu MO, Sencan O, Bozkurt A. Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother 2006;18:421-4.
25. Elkiran T, Harputluoglu H, Yasar U, Babaoglu MO, Dincel AK, Altundag K et al. Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients. Methods Find Exp Clin Pharmacol 2007;29:27-32.
26. Caraco Y, Sheller J, Wood AJ. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J Pharmacol Exp Ther 1999;290:413-22.
27. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990;11:116-28.
28. Ratz Bravo AE, Tchambaz L, Krahenbuhl-Melcher A, Hess L, Schlienger RG, Krahenbuhl S. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf 2005;28:263-75.
29. Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006;23:506-12.
30. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001;40:263-81.
31. Mc Donnell CG, Harte S, O'Driscoll J, O'Loughlin C, Van Pelt FN, Shorten GD. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia 2003;58:899-904.
32. Stern RH, Smithers JA, Olson SC. Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine. J Clin Pharmacol 1998;38:753-7.
33. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9.
34. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7.
35. Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007;50:291-5.
36. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10:187-216.
37. Gunes A, Bilir E, Zengil H, Babaoglu MO, Bozkurt A, Yasar U. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic Clin Pharmacol Toxicol 2007;100:383-6.
38. Yasar U, Babaoglu MO, Bozkurt A. Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1). Basic Clin Pharmacol Toxicol 2008;103:176-9.
39. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003;73:517-28.
40. Yasar U, Dahl ML, Christensen M, Eliasson E. Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity. Br J Clin Pharmacol 2002;54:183-5.
41. Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Reed K et al. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 1998;18:198-207.
42. Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 2010;11:323-32.